Rituximab produces high overall and complete response rates and longer progression-free survival than that reported for standard treatment of indolent non-Hodgkin’s lymphoma (NHL), according to a report in the Oct. 15 issue of the Journal of Clinical Oncology. Investigators suggest that this should be first-line therapy, pending additional studies to evaluate its role in combination with chemotherapy.
“The results of this multicenter phase II trial, now with minimum follow-up of 24 months, confirm the high level of activity with single-agent rituximab in the first-line treatment of patients with indolent NHL,” write John D. Hainsworth, MD, from the Sarah Cannon Cancer Center in Nashville, Tennessee, and colleagues.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!